The future of type 1 cannabinoid receptor allosteric ligands

References

• Ahn KH, Mahmoud MM, Kendall DA. 2012. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. J Biol Chem. 287:12070–12082.
   PubMed Web of Science ®Google Scholar
• Ahn KH, Mahmoud MM, Shim JY, Kendall DA. 2013. Distinct roles of β-arrestin 1 and β-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1). J Biol Chem. 288:9790–9800.
   PubMed Web of Science ®Google Scholar
• Anavi-Goffer S, Baillie G, Irving AJ, Gertsch J, Greig IR, Pertwee RG, Ross RA. 2012. Modulation of l-a-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J Biol Chem. 287:91–104.
   PubMed Web of Science ®Google Scholar
• Bagher AM, Laprairie RB, Kelly ME, Denovan-Wright EM. 2012. Coexpression of the human cannabinoid receptor coding region splice variants (hCB1) affects the function of hCB1 receptor complexes. Eur J Pharmacol. 721:341–354.
   Web of Science ®Google Scholar
• Bagher AM, Laprairie RB, Toguri JT, Kelly MEM, Denovan-Wright EM. 2017. Bidirectional allosteric interactions between cannabinoid receptor 1 (CB1) and dopamine receptor 2 long (D2L) heterotetramers. Eur J Pharmacol. 813:66–83.
   PubMed Web of Science ®Google Scholar
• Baillie GL, Horswill JG, Anavi-Goffer S, Reggio PH, Bolognini D, Abood ME, McAllister S, Strange PG, Stephens GJ, Pertwee RG, et al. 2012. CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol. 83:322–338.
   PubMed Web of Science ®Google Scholar
• Bauer M, Chicca A, Tamborrini M, Eisen D, Lerner R, Lutz B, Poetz O, Pluschke G, Gertsch J. 2012. Identification and quantification of a new family of peptide endocannabinoids (pepcans) showing negative allosteric modulation at CB1 receptors. J Biol Chem. 287:36944–36967.
   PubMed Web of Science ®Google Scholar
• Bertini S, Chicca A, Gado F, Arena C, Nieri D, Digiacomo M, Saccomanni G, Zhao P, Abood ME, Macchia M, et al. 2017. Novel analogs of PSNCBAM-1 as allosteric modulators of cannabinoid CB1 receptor. Bioorg Med Chem. 25:6427–6434.
   PubMed Web of Science ®Google Scholar
• Black JW, Leff P. 1983. Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci. 220:141–162.
   PubMed Web of Science ®Google Scholar
• Buckner JD, Heimberg RG, Schneier FR, Liu S-M, Wang S, Blanco C. 2012. The relationship between cannabis use disorders and social anxiety disorder in the National Epidemiological Study of Alcohol and Related Conditions (NESARC). Drug Alcohol Dep. 124:128–134.
   PubMed Web of Science ®Google Scholar
• Busquets-Garcia A, Soria-Gómez E, Redon B, Mackenbach Y, Vallée M, Chaoloff F, Varilh M, Ferreira G, Piazza PV, Mariscano G. 2017. Pregnenolone blocks cannabinoid-induced acute psychotic-like states in mice. Mol Psychiatry. 22:1594–1603.
   PubMed Web of Science ®Google Scholar
• Cairns EA, Szczesniak AM, Straiker AJ, Kulkarni PM, Pertwee RG, Thakur GA, Baldridge WH, Kelly MEM. 2017. The in vivo effects of the CB1-positive allosteric modulator GAT229 on intraocular pressure in ocular normotensive and hypertensive mice. J Ocul Pharmacol Ther. 33:582–590.
   PubMed Web of Science ®Google Scholar
• Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS. 2012. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Phil Trans R Soc Lond B Biol Sci. 367:3364–3378.
   PubMed Web of Science ®Google Scholar
• Cawston EE, Redmond WJ, Breen CM, Grimsey NL, Connor M, Glass M. 2014. Real-time characterization of cannabinoid receptor (CB1) allosteric modulators reveals novel mechanism of action. Br J Pharmacol. 170:893–907.
   Web of Science ®Google Scholar
• Christopoulos A, Kenakin T. 2002. G protein-coupled receptor allosterism and complexing. Pharmacol Rev. 54:323–374.
   PubMed Web of Science ®Google Scholar
• Congreve M, Oswald C, Marshall FH. 2017. Applying structure-based drug design approaches to allosteric modulators of GPCRs. Trends Pharmacol Sci. 38:837–847.
   PubMed Web of Science ®Google Scholar
• Ding Y, Qiu Y, Jing L, Thorn DA, Zhang Y, Li JX. 2014. Behavioral effects of the cannabinoid CB1 receptor allosteric modulator ORG27569 in rats. Pharmacol Res Perspect. 2:e00069.
   PubMedGoogle Scholar
• Dvorácskó S, Tömböly Y, Berkecz R, Keresztes A. 2016. Investigation of receptor binding and functional characteristics of hemopressin(1–7). Neuropeptides. 58:15–22.
   PubMed Web of Science ®Google Scholar
• Fay JF, Farrens DL. 2012. A key agonist-induced conformational change in the cannabinoid receptor CB1 is blocked by the allosteric ligand Org 27569. J Biol Chem. 287:33873–33882.
   PubMed Web of Science ®Google Scholar
• Fay JF, Farrens DL. 2013. The membrane proximal region of the cannabinoid receptor CB1 N-terminus can allosterically modulate ligand affinity. Biochemistry. 52:8286–8294.
   PubMed Web of Science ®Google Scholar
• Fay JF, Farrens DL. 2015. Structural dynamics and energetics underlying allosteric inactivation of the cannabinoid receptor CB1. Proc Natl Acad Sci USA. 112:8469–8479.
   PubMed Web of Science ®Google Scholar
• Fay JF, Farrens DL. 2017. Purification of functional CB1 and analysis by site-directed fluorescence labeling methods. Meth Enzymol. 593:343–370.
   PubMed Web of Science ®Google Scholar
• Gamage TF, Ignatowska-Jankowska BM, Wiley JL, Abdelrahman M, Trembleau L, Greig IR, Thakur GA, Tichkule R, Polkis J, Ross RA, et al. 2014. In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. Behav Pharmacol. 25:182–185.
   PubMed Web of Science ®Google Scholar
• Gamage TF, Farquhar CE, Lefever TW, Thomas BF, Nguyen T, Zhang Y, Wiley JL. 2017. The great divide: separation between in vitro and in vivo effects of PSNCBAM-based CB1 receptor allosteric modulators. Neuropharmacology. 125:365–375.
   PubMed Web of Science ®Google Scholar
• German N, Decker AM, Gilmour BP, Gay EA, Wiley JL, Thomas BF, Zhang Y. 2014. Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure–activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1). J Med Chem. 57:7758–7769.
   PubMed Web of Science ®Google Scholar
• Glass M, Felder CC. 1997. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci. 17:5327–5333.
   PubMed Web of Science ®Google Scholar
• Greig IR, Baillie GL, Abdelrahman M, Trembleau L, Ross RA. 2016. Development of indole sulfonamides as cannabinoid receptor negative allosteric modulators. Bioorg Med Chem Lett. 26:4403–4407.
   PubMed Web of Science ®Google Scholar
• Hassing HA, Fares S, Larsen O, Pad H, Hauge M, Jones RM, Schwartz TW, Hansen HS, Rosenkilde MM. 2016. Biased signaling of lipids and allosteric actions of synthetic molecules for GPR119. Biochem Pharmacol. 119:66–75.
   PubMed Web of Science ®Google Scholar
• Horswill JG, Bali U, Shaaban S, Keily JF, Jeevaratnam P, Babbs AJ, Reynet C, Wong Kai In P. 2007. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol. 152:805–814.
   PubMed Web of Science ®Google Scholar
• Hua T, Vemuri K, Nikas SP, Laprairie RB, Wu Y, Qu L, Pu M, Korde A, Jiang S, Ho J-H, et al. 2017. Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature. 547:468–471.
   PubMed Web of Science ®Google Scholar
• Hua T, Vemuri K, Pu M, Qu L, Han GW, Wu Y, Zhao S, Shui W, Li S, Korde A, et al. 2016. Crystal structure of the human cannabinoid receptor CB1. Cell. 167:750–762.
   PubMed Web of Science ®Google Scholar
• Hudson BD, Christiansen E, Murdoch H, Jenkins L, Hansen AH, Madsen O, Ulven T, Milligan G. 2014. Complex pharmacology of novel allosteric free fatty acid 3 receptor ligands. Mol Pharmacol. 86:200–210.
   PubMed Web of Science ®Google Scholar
• Hudson BD, Hébert TE, Kelly ME. 2010. Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors. Br J Pharmacol. 160:627–642.
   PubMed Web of Science ®Google Scholar
• Ignatowska-Jankowska BM, Baillie GL, Kinsey S, Crowe M, Ghosh S, Owens RA, Damaj IM, Poklis J, Wiley JL, Zanda M, et al. 2015. A cannabinoid CB1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects. Neuropsychopharmacology. 40:2948–2959.
   PubMed Web of Science ®Google Scholar
• Iliff HA, Lynch DL, Kotsikorou E, Reggio PH. 2011. Parameterization of Org27569: an allosteric modulator of the cannabinoid CB1 G protein-coupled receptor. J Comput Chem. 32:2119–2126.
   PubMed Web of Science ®Google Scholar
• Jing L, Qiu Y, Zhang Y, Li JX. 2014. Effects of the cannabinoid CB1 receptor allosteric modulator ORG 27569 on reinstatement of cocaine- and methamphetamine-seeking behavior in rats. Drug Alcohol Depend. 143:251–256.
   PubMed Web of Science ®Google Scholar
• Kathmann M, Flau K, Redmer A, Tränkle C, Schlicker E. 2006. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol. 372:354–361.
   PubMed Web of Science ®Google Scholar
• Kavia RB, De Ridder D, Constantinescu CS, Stott CG, Fowler CJ. 2010. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler. 16:1349–1359.
   PubMed Web of Science ®Google Scholar
• Kenakin T. 2015. Gaddum memorial lecture 2014: receptors as an evolving concept: from switches to biased microprocessors. Br J Pharmacol. 172:4238–4253.
   PubMed Web of Science ®Google Scholar
• Kenakin T. 2017. Theoretical aspects of GPCR–ligand complex pharmacology. Chem Rev. 117:4–20.
   PubMed Web of Science ®Google Scholar
• Keov P, Sexton PM, Christopoulos A. 2011. Allosteric modulator of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology. 60:24–35.
   PubMed Web of Science ®Google Scholar
• Khajehali E, Malone DT, Glass M, Sexton PM, Christopoulos A, Leach K. 2015. Biased agonism and biased allosteric modulation at the CB1 cannabinoid receptor. Mol Pharmacol. 88:368–379.
   PubMed Web of Science ®Google Scholar
• Khurana L, Ali HI, Olszewska T, Ahn KH, Damaraju A, Kendall DA, Lu D. 2014. Optimization of chemical functionalities of indole-2-carboxamides to improve allosteric parameters for the cannabinoid receptor 1 (CB1). J Med Chem. 57:3040–3052.
   PubMed Web of Science ®Google Scholar
• Khurana L, Fu BQ, Duddupudi AL, Liao YH, Immadi SS, Kendall DA, Lu D. 2017. Pyrimidinyl biphenylureas: identification of new lead compounds as allosteric modulators of the cannabinoid receptor CB1. J Med Chem. 60:1089–1104.
   PubMed Web of Science ®Google Scholar
• Klein Herenbrink C, Sykes DA, Donthamsetti P, Canals M, Coudrat T, Shonberg J, Scammells PJ, Capuano B, Sexton PM, et al. 2016. The role of kinetic context in apparent biased agonism at GPCRs. Nat Commun. 7:10842.
   PubMed Web of Science ®Google Scholar
• Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D. 2014. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 82:1556–1563.
   PubMed Web of Science ®Google Scholar
• Kulkarni PM, Kulkarni AR, Korde A, Tichkule RB, Laprairie RB, Denovan-Wright EM, Zhou H, Janero DR, Zvonok N, Makriyannis A. 2016. Novel electrophilic and photoaffinity covalent probes for mapping the cannabinoid 1 receptor allosteric site(s). J Med Chem. 59:44–60.
   PubMed Web of Science ®Google Scholar
• Kulkarni PM, Ranade A, Garai S, Thakur GA. 2017. Microwave-accelerated conjugate addition of 2-arylindoles to substituted β-nitrostyrenes in the presence of ammonium trifluoroacetate: an efficient approach for the synthesis of a novel class of CB1 cannabinoid receptor allosteric modulators. J Heterocycl Chem. 54:2079–2084.
   Web of Science ®Google Scholar
• Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM. 2016. Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease. Mol Pharmacol. 89:364–275.
   PubMed Web of Science ®Google Scholar
• Laprairie RB, Bagher AM, Denovan-Wright EM. 2016. Cannabinoid receptor ligand bias: implications in the central nervous system. Curr Opin Pharmacol. 32:32–43.
   PubMed Web of Science ®Google Scholar
• Laprairie RB, Kulkarni AR, Kulkarni PM, Hurst DP, Lynch D, Reggio PH, Janero DR, Pertwee RG, Stevenson LA, Kelly ME, et al. 2016. Mapping cannabinoid 1 receptor allosteric site(s): critical molecular determinant and signaling profile of GAT100, a novel, potent, and irreversibly binding probe. ACS Chem Neurosci. 7:776–798.
   PubMed Web of Science ®Google Scholar
• Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM. 2015. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 172:4790–4805.
   PubMed Web of Science ®Google Scholar
• Laprairie RB, Zrein A, Bagher AM, Kulkarni PM, Thakur GA, Kelly ME, Denovan-Wright EM. 2015. Enantiomer-specific positive allosteric modulation of the type 1 cannabinoid receptor for the treatment of Huntington disease. Abstract in International Cannabinoid Research Symposium 2015, Wolfville NS Can.
   Google Scholar
• Laprairie RB, Kelly MEM, Denovan-Wright EM. 2017. Differences in the pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 cannabinoid receptor CB1R. Abstract in Pharmacology 2017: London, UK.
   Google Scholar
• Laprairie RB, Kulkarni PM, Deschamps JR, Kelly MEM, Janero DR, Cascio MG, Stevenson LA, Pertwee RG, Kenakin TP, Denovan-Wright EM, et al. 2017. Enantiospecific allosteric modulation of cannabinoid 1 receptor. ACS Chem Neurosci. 8:1188–1203.
   PubMed Web of Science ®Google Scholar
• Mahmoud MM, Ali HI, Ahn KH, Damaraju A, Samala S, Pulipati VK, Kolluru S, Kendall DA, Lu D. 2013. Structure–activity relationship study of indole-2-carboxamides identifies a potent allosteric modulator for the cannabinoid receptor 1 (CB1). J Med Chem. 56:7965–7975.
   PubMed Web of Science ®Google Scholar
• Martínez-Pinilla E, Varani K, Reyes-Resina I, Angelats E, Vincezi F, Ferreiro-Vera C, Oyarzabal J, Canela EI, Lanciego JL, et al. 2017. Binding and signaling studies disclose potential allosteric site for cannabidiol in cannabinoid CB2 receptors. Front Pharmacol. 8:744.
   PubMed Web of Science ®Google Scholar
• McPartland JM, Duncan M, Di Marzo V, Pertwee R. 2014. Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 172:737–753.
   Web of Science ®Google Scholar
• Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. 2007. Cannabidiol-recent advances. Chem Biodivers. 4:1678–1692.
   PubMed Web of Science ®Google Scholar
• Moreno JLL-S, Caldentey JG, Cubillo PT, Romero CR, Ribas GG, Arias MAA, de Yébenes MJG, Tolón RM, Galve-Roperh I, Sagredo O, et al. 2016. A double-blind, cross-over, placebo-controlled, phase II trial with Sativex in Huntington’s disease. J Neurol. 263:1390–1400.
   PubMed Web of Science ®Google Scholar
• Nguyen T, German N, Decker AM, Langston TL, Gamage TF, Farquhar CE, Li JX, Wiley JL, Thomas BF, Zhang Y. 2017. Novel diarylurea based allosteric modulators of the cannabinoid CB1 receptor: evaluation of importance of 6-pyrrolidinylpyridinyl substitution. J Med Chem. 60:7410–7424.
   PubMed Web of Science ®Google Scholar
• Nguyen T, German N, Decker AM, Li JX, Wiley JL, Thomas BF, Kenakin TP, Zhang Y. 2015. Structure–activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators. Bioorg Med Chem. 23:2195–2203.
   PubMed Web of Science ®Google Scholar
• Pamplona FA, Ferriera J, Menezes de Lima O, Jr., Duarte FS, Bento AF, Forner S, Villarinho JG, Bellochio L, Wotjak CT, Lerner R, et al. 2012. Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proc Natl Acad Sci. 109:21134–21139.
   PubMed Web of Science ®Google Scholar
• Pertwee RG. 2008. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci. 76:1307–1324.
   Web of Science ®Google Scholar
• Pertwee RG, Ross RA, Craib SJ, Thomas A. 2002. (–)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol. 456:99–106.
   PubMed Web of Science ®Google Scholar
• Petrucci V, Chicca A, Glasmacher S, Paloczi J, Cao Z, Pacher P, Gertsch J. 2017. Pepcan-12 (RVD-hemopressin) is a CB2 receptor positive allosteric modulator constitutively secreted by adrenals and in liver upon tissue damage. Sci Rep. 7:9560.
   PubMed Web of Science ®Google Scholar
• Piscitelli F, Ligresti A, La Regina G, Coluccia A, Morera L, Allarà M, Novellino E, Di Marzo V, Silvestri R. 2012. Indole-2-carboxamides as allosteric modulators of the cannabinoid CB1 receptor. J Med Chem. 55:5627–5631.
   PubMed Web of Science ®Google Scholar
• Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, McLean A, McIntosh L, Goodwin G, Walker G, et al. 2005. Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol. 68:1484–1495.
   PubMed Web of Science ®Google Scholar
• Qiao CJ, Ali HI, Ahn KH, Kolluru S, Kendall DA, Lu D. 2016. Synthesis and biological evaluation of indole-2-carboxamides bearing photoactivatable functionalities as novel allosteric modulators for the cannabinoid CB1 receptor. Eur J Med Chem. 211:517–529.
   Web of Science ®Google Scholar
• Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, NéLiat G, Caput D, et al. 1994. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:240–244.
   PubMed Web of Science ®Google Scholar
• Rosenberg EC, Patra PH, Whalley BJ. 2017. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Epilepsy Behav. 70:319–327.
   PubMed Web of Science ®Google Scholar
• Russo EB, Burnett A, Hall B, Parker KK. 2005. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 30:1037–1043.
   PubMed Web of Science ®Google Scholar
• Ryan D, Drysdale AJ, Pertwee RG, Platt B. 2007. Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue. Eur J Neurosci. 25:2093–2102.
   PubMed Web of Science ®Google Scholar
• Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ. 2007. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 152:1092–1101.
   PubMed Web of Science ®Google Scholar
• Sabatucci A, Tortolani D, Dainese E, Maccarrone M. 2017. In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor. Biotechnol Appl Biochem. DOI:10.1002/bab.1589.
   PubMed Web of Science ®Google Scholar
• Shao Z, Yin J, Chapman K, Grzemska M, Clark L, Wang J, Rosenbaum DM. 2016. High-resolution crystal structure of the human CB1 cannabinoid receptor. Nature. 540:602–606.
   PubMed Web of Science ®Google Scholar
• Shore DM, Baillie GL, Hurst DH, Navas F 3rd, Seltzman HH, Marcu JP, Abood ME, Ross RA, Reggio PH. 2014. Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling. J Biol Chem. 289:5828–5845.
   PubMed Web of Science ®Google Scholar
• Slivicki RA, Xu Z, Kulkarni PM, Pertwee RG, Mackie K, Thakur GA, Hohmann AG. 2017. Positive allosteric modulation of cannabinoid receptor type 1 suppresses pathological pain without producing tolerance or dependence. Biol Psychiatry. DOI:10.1016/j.biopsych.2017.06.032.
   PubMed Web of Science ®Google Scholar
• Smith NJ, Ward RJ, Stoddart LA, Hudson BD, Kostenis E, Ulven T, Morris JC, Tränkle C, Tikhonova IG, Adams DR, Milligan G. 2011. Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator. Mol Pharmacol. 80:163–173.
   PubMed Web of Science ®Google Scholar
• Straiker A, Mitjavila J, Yin D, Gibson A, Mackie K. 2015. Aiming for allosterism: evaluation of allosteric modulators of CB1 in a neuronal model. Pharmacol Res. 99:370–376.
   PubMed Web of Science ®Google Scholar
• Vallée M, Vitiello S, Bellocchio L, Hebert-Chatelain E, Monlezun S, Martin-Garcia E, Kasanetz F, Baillie GL, Panin F, Cathala A, et al. 2014. Pregnenolone can protect the brain from cannabis intoxication. Science. 343:94–98.
   PubMed Web of Science ®Google Scholar
• Wang X, Horswill JG, Whalley BJ, Stephens GJ. 2011. Effects of the allosteric antagonist 1-(4-chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea (PSNCBAM-1) on CB1 receptor modulation in the cerebellum. Mol Pharmacol. 79:758–767.
   PubMed Web of Science ®Google Scholar
• Wootten D, Christopoulos A, Sexton PM. 2013. Emerging paradigms in GPCR allostery: implications for drug discovery. Nat Rev Drug Discov. 12:630–644.
   PubMed Web of Science ®Google Scholar
• Yamasaki T, Fujinaga M, Shimoda Y, Mori W, Zhang Y, Wakizaka H, Ogawa M, Zhang MR. 2017. Radiosynthesis and evaluation of new PET ligands for peripheral cannabinoid receptor type 1 imaging. Bioorg Med Chem Lett. 27:4114–4117.
   PubMed Web of Science ®Google Scholar
• Yekkirala AS, Roberson DP, Bean BP, Woolf CJ. 2017. Breaking barriers to novel analgesic drug development. Nat Rev Drug Discov. 16:545–564.
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Crippa JA, Hallak JE. 2009. Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol (Oxford). 23:979–983.
   PubMed Web of Science ®Google Scholar